About the Problem Statement:
One of the future growth pillars for Mitsubishi Chemical Holdings Corporation’s (MCHC) healthcare business is to provide ‘around the pill solutions’ enabled by digital technology, intended to improve the quality of life of patients and their families, in their core therapeutics areas. Therapeutics areas of interest include the central nervous system (especially neuromuscular disease), autoimmune diseases and metabolic diseases.
Objectives:
To establish multiple touchpoints with patients during the patient journey from prevention to prognosis, to collect and analyse healthcare data and expand the value of current treatments.
Examples of such solutions could be digital platforms enabling patient-centric disease management, electronic patient-reported outcomes, digital diagnostics, disease tracking, digital medication management, digital biomarker, etc.
Working Model:
MCHC is open to strategic investments as well as partnership opportunities with digital health startups in Asia Pacific who have their product ready for a feasibility study.
